Dicerna Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DRNA)

$8.42 -0.01 (-0.12 %)
(As of 01/16/2018 04:42 AM ET)
Previous Close$8.43
Today's Range$8.29 - $8.72
52-Week Range$2.42 - $10.24
Volume132,700 shs
Average Volume291,622 shs
Market Capitalization$434.82 million
P/E Ratio-2.45
Dividend YieldN/A
Beta2.84

About Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals logoDicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:DRNA
CUSIPN/A
Phone+1-617-6218097

Debt

Debt-to-Equity RatioN/A
Current Ratio7.59%
Quick Ratio7.59%

Price-To-Earnings

Trailing P/E Ratio-2.45481049562682
Forward P/E Ratio-2.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales1,499.34
Cash FlowN/A
Price / CashN/A
Book Value$1.99 per share
Price / Book4.23

Profitability

Trailing EPS($3.43)
Net Income$-59,510,000.00
Net Margins-5,895.26%
Return on Equity-293.25%
Return on Assets-87.25%

Miscellaneous

Employees47
Outstanding Shares51,640,000

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.22. The biopharmaceutical company had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. Dicerna Pharmaceuticals's quarterly revenue was up 192.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.68) earnings per share. View Dicerna Pharmaceuticals' Earnings History.

When will Dicerna Pharmaceuticals make its next earnings announcement?

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 28th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

Where is Dicerna Pharmaceuticals' stock going? Where will Dicerna Pharmaceuticals' stock price be in 2018?

4 brokers have issued twelve-month price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $7.00 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.

What are Wall Street analysts saying about Dicerna Pharmaceuticals stock?

Here are some recent quotes from research analysts about Dicerna Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (11/7/2017)
  • 2. Cowen Inc analysts commented, "DRNA reported 1Q17 results today." (5/9/2017)

Who are some of Dicerna Pharmaceuticals' key competitors?

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the folowing people:

  • David M. Madden Ph.D., Independent Chairman of the Board (Age 53)
  • Douglas M. Fambrough Ph.D., President, Chief Executive Officer, Director (Age 46)
  • John B. Green, Chief Financial Officer, Principal Financial Officer (Age 62)
  • Bob D. Brown Ph.D., Senior Vice President, Chief Scientific Officer (Age 50)
  • Theodore T. Ashburn M.D., Ph.D., Senior Vice President - Product Strategy & Operations (Age 47)
  • Pankaj Bhargava M.D., Chief Medical Officer (Age 46)
  • Ralf H. Rosskamp M.D., Chief Medical Officer (Age 63)
  • James B. Weissman, Chief Business Officer (Age 53)
  • Martin I Freed M.D., Independent Director (Age 54)
  • Brian K. Halak Ph.D., Independent Director (Age 45)

Who owns Dicerna Pharmaceuticals stock?

Dicerna Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include RA CAPITAL MANAGEMENT, LLC (9.90%), RA CAPITAL MANAGEMENT, LLC (19.90%) and DOMAIN PARTNERS VIII, L.P. (6.80%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

How do I buy Dicerna Pharmaceuticals stock?

Shares of Dicerna Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of Dicerna Pharmaceuticals stock can currently be purchased for approximately $8.42.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $434.82 million and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-59,510,000.00 in net income (profit) each year or ($3.43) on an earnings per share basis. Dicerna Pharmaceuticals employs 47 workers across the globe.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 87 Cambridgepark Dr, CAMBRIDGE, MA 02140-2311, United States. The biopharmaceutical company can be reached via phone at +1-617-6218097 or via email at [email protected]


MarketBeat Community Rating for Dicerna Pharmaceuticals (DRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dicerna Pharmaceuticals (NASDAQ:DRNA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.602.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$7.00$5.33$6.50
Price Target Upside: 3.18% downside3.18% downside63.60% upside98.17% upside

Dicerna Pharmaceuticals (NASDAQ:DRNA) Consensus Price Target History

Price Target History for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017HC WainwrightReiterated RatingBuy -> Buy$6.00 -> $10.00N/AView Rating Details
8/14/2017Chardan CapitalReiterated RatingHoldMediumView Rating Details
5/9/2017CowenReiterated RatingBuyHighView Rating Details
4/2/2017Jefferies GroupReiterated RatingBuy$8.00 -> $7.00LowView Rating Details
2/1/2017Leerink SwannReiterated RatingMkt PerformN/AView Rating Details
9/28/2016Stifel NicolausReiterated RatingBuy$13.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earnings History and Estimates Chart

Earnings by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ DRNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2018($0.65)N/AView Earnings Details
11/2/2017Q3 2017($0.70)($0.92)$0.47 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.61)($1.15)$0.08 million$0.25 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.65)($0.68)$0.08 million$0.13 millionViewListenView Earnings Details
3/30/2017Q4 2016($0.73)($0.68)$0.13 millionViewN/AView Earnings Details
11/7/2016Q316($0.87)($0.68)$162.00 millionViewListenView Earnings Details
8/4/2016Q216($0.84)($0.75)ViewN/AView Earnings Details
5/9/2016Q116($0.86)($0.76)ViewN/AView Earnings Details
3/10/2016Q415($0.84)($0.76)$2.50 millionViewListenView Earnings Details
11/10/2015Q315($0.84)($0.82)ViewListenView Earnings Details
8/6/2015Q215($0.78)($0.86)$0.18 millionViewN/AView Earnings Details
5/11/2015Q1($0.73)($0.79)$600.00 millionViewListenView Earnings Details
3/12/2015Q414($0.57)($0.63)$1.45 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.63)($0.63)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.42)($0.64)ViewN/AView Earnings Details
5/13/2014Q114($0.52)($0.76)ViewN/AView Earnings Details
3/27/2014($0.62)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Dicerna Pharmaceuticals (NASDAQ:DRNA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.75)($0.75)($0.75)
Q2 20181($0.75)($0.75)($0.75)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.46)($0.46)($0.46)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Dicerna Pharmaceuticals (NASDAQ:DRNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 29.41%
Institutional Ownership Percentage: 21.93%
Insider Trades by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Bain Capital Life Sciences InvDirectorBuy285,000$7.00$1,995,000.00View SEC Filing  
11/16/2016Dennis LangerDirectorSell23,766$3.52$83,656.3243,595View SEC Filing  
11/15/2016Douglas FambroughCEOBuy33,100$3.71$122,801.00View SEC Filing  
5/12/2016James B WeissmanInsiderBuy5,000$3.29$16,450.0015,100View SEC Filing  
11/25/2014James E FlynnInsiderSell321,965$11.36$3,657,522.40View SEC Filing  
11/7/2014James E FlynnInsiderSell214,164$9.05$1,938,184.20View SEC Filing  
10/15/2014James E FlynnInsiderSell117,778$10.86$1,279,069.08View SEC Filing  
10/14/2014James E FlynnMajor ShareholderSell36,115$11.02$397,987.30View SEC Filing  
10/10/2014James E FlynnMajor ShareholderSell30,214$12.13$366,495.82View SEC Filing  
2/4/2014James E FlynnInsiderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
2/4/2014Stephen J HoffmanDirectorBuy200,000$15.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines

Source:
DateHeadline
Dicerna Pharmaceuticals (DRNA) & Auris Medical (EARS) Critical ComparisonDicerna Pharmaceuticals (DRNA) & Auris Medical (EARS) Critical Comparison
www.americanbankingnews.com - January 15 at 11:16 PM
Dicerna Pharmaceuticals Inc (DRNA) Given Average Rating of "Hold" by AnalystsDicerna Pharmaceuticals Inc (DRNA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 12 at 6:32 PM
$5.18 Million in Sales Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter$5.18 Million in Sales Expected for Dicerna Pharmaceuticals Inc (DRNA) This Quarter
www.americanbankingnews.com - January 6 at 3:38 AM
Zacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) to Announce -$0.64 EPSZacks: Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) to Announce -$0.64 EPS
www.americanbankingnews.com - January 4 at 3:26 PM
Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher - NasdaqDicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher - Nasdaq
www.nasdaq.com - December 30 at 9:17 AM
Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% HigherDicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher
finance.yahoo.com - December 28 at 3:57 PM
INFI Picks Up Steam, HAIR Grows, MRSN Awaits Safety Data, SPPI AdvancesINFI Picks Up Steam, HAIR Grows, MRSN Awaits Safety Data, SPPI Advances
www.nasdaq.com - December 27 at 11:56 PM
Dicerna Pharmaceuticals Inc (DRNA) Expected to Announce Quarterly Sales of $5.18 MillionDicerna Pharmaceuticals Inc (DRNA) Expected to Announce Quarterly Sales of $5.18 Million
www.americanbankingnews.com - December 21 at 3:00 PM
[$$] Bain Makes Bank in Two Rebounding Biotechs[$$] Bain Makes Bank in Two Rebounding Biotechs
finance.yahoo.com - December 21 at 9:23 AM
Dicerna Pharmaceuticals Inc (DRNA) Director Purchases $1,995,000.00 in StockDicerna Pharmaceuticals Inc (DRNA) Director Purchases $1,995,000.00 in Stock
www.americanbankingnews.com - December 19 at 5:26 PM
Dicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Buy" from BrokeragesDicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 18 at 8:24 PM
Analyzing Dicerna Pharmaceuticals (DRNA) & Its PeersAnalyzing Dicerna Pharmaceuticals (DRNA) & Its Peers
www.americanbankingnews.com - December 17 at 11:36 PM
Comparing Dicerna Pharmaceuticals (DRNA) and The CompetitionComparing Dicerna Pharmaceuticals (DRNA) and The Competition
www.americanbankingnews.com - December 16 at 1:30 AM
ETFs with exposure to Dicerna Pharmaceuticals, Inc. : December 14, 2017ETFs with exposure to Dicerna Pharmaceuticals, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:57 PM
Dicerna Pharma (DRNA) Announces Proposed Common Share OfferingDicerna Pharma (DRNA) Announces Proposed Common Share Offering
www.streetinsider.com - December 14 at 9:33 AM
With -20.9% EPS Drop, Should Dicerna Pharmaceuticals Inc’s (NASDAQ:DRNA) Recent Track Record Be A Cause Of Concern?With -20.9% EPS Drop, Should Dicerna Pharmaceuticals Inc’s (NASDAQ:DRNA) Recent Track Record Be A Cause Of Concern?
finance.yahoo.com - December 14 at 9:33 AM
Dicerna Announces Pricing of Follow-On Public Offering of Common StockDicerna Announces Pricing of Follow-On Public Offering of Common Stock
finance.yahoo.com - December 14 at 9:33 AM
Head-To-Head Comparison: Dicerna Pharmaceuticals (DRNA) and Its PeersHead-To-Head Comparison: Dicerna Pharmaceuticals (DRNA) and Its Peers
www.americanbankingnews.com - December 12 at 11:16 PM
Head to Head Contrast: Dicerna Pharmaceuticals (DRNA) and Its RivalsHead to Head Contrast: Dicerna Pharmaceuticals (DRNA) and Its Rivals
www.americanbankingnews.com - December 8 at 5:36 AM
 Brokerages Anticipate Dicerna Pharmaceuticals, Inc. (DRNA) Will Announce Quarterly Sales of $5.18 Million Brokerages Anticipate Dicerna Pharmaceuticals, Inc. (DRNA) Will Announce Quarterly Sales of $5.18 Million
www.americanbankingnews.com - December 2 at 2:22 AM
 Analysts Expect Dicerna Pharmaceuticals, Inc. (DRNA) to Announce -$0.64 EPS Analysts Expect Dicerna Pharmaceuticals, Inc. (DRNA) to Announce -$0.64 EPS
www.americanbankingnews.com - November 30 at 11:22 PM
ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 28, 2017ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 28, 2017
finance.yahoo.com - November 28 at 5:23 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Given Average Recommendation of "Buy" by AnalystsDicerna Pharmaceuticals, Inc. (DRNA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 23 at 10:06 PM
Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceDicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 21 at 6:15 PM
Dicerna Pharmaceuticals (DRNA) Presents At Stifel 2017 Healthcare Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 12:52 PM
SGMO Emerges Champion, Mark Your Calendar For ANTH, No Stopping NKTRSGMO Emerges Champion, Mark Your Calendar For ANTH, No Stopping NKTR
www.finanznachrichten.de - November 16 at 1:35 PM
$5.18 Million in Sales Expected for Dicerna Pharmaceuticals, Inc. (DRNA) This Quarter$5.18 Million in Sales Expected for Dicerna Pharmaceuticals, Inc. (DRNA) This Quarter
www.americanbankingnews.com - November 14 at 6:26 AM
-$0.64 Earnings Per Share Expected for Dicerna Pharmaceuticals, Inc. (DRNA) This Quarter-$0.64 Earnings Per Share Expected for Dicerna Pharmaceuticals, Inc. (DRNA) This Quarter
www.americanbankingnews.com - November 12 at 11:10 AM
Dicerna to Present at the Stifel 2017 Healthcare ConferenceDicerna to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 9 at 1:16 AM
ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 8, 2017ETFs with exposure to Dicerna Pharmaceuticals, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 1:16 AM
Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Dicerna Pharmaceuticals, Inc. :DRNA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 8 at 2:47 AM
Dicerna Pharmaceuticals, Inc. (DRNA) Downgraded by Zacks Investment ResearchDicerna Pharmaceuticals, Inc. (DRNA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 7 at 11:10 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Expected to Earn Q1 2018 Earnings of ($0.75) Per ShareDicerna Pharmaceuticals, Inc. (DRNA) Expected to Earn Q1 2018 Earnings of ($0.75) Per Share
www.americanbankingnews.com - November 6 at 10:22 AM
Dicerna Pharmaceuticals, Inc. (DRNA) Stock Rating Reaffirmed by HC WainwrightDicerna Pharmaceuticals, Inc. (DRNA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 5 at 6:20 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Releases Quarterly  Earnings Results, Misses Expectations By $0.22 EPSDicerna Pharmaceuticals, Inc. (DRNA) Releases Quarterly Earnings Results, Misses Expectations By $0.22 EPS
www.americanbankingnews.com - November 4 at 12:48 AM
Dicerna Pharmaceuticals Reaches Analyst Target PriceDicerna Pharmaceuticals Reaches Analyst Target Price
www.thestreet.com - November 3 at 11:50 PM
Edited Transcript of DRNA earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of DRNA earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 1:38 PM
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
finance.yahoo.com - November 2 at 7:04 PM
Dicerna Pharmaceuticals, Inc. to Host Earnings CallDicerna Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 2 at 7:04 PM
Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate UpdateDicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update
finance.yahoo.com - November 2 at 7:04 PM
Dicerna Pharmaceuticals posts 3Q lossDicerna Pharmaceuticals posts 3Q loss
finance.yahoo.com - November 2 at 7:04 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Scheduled to Post Quarterly Earnings on MondayDicerna Pharmaceuticals, Inc. (DRNA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:14 AM
Dicerna to Report Third Quarter 2017 Financial Results and Host Conference Call on November 2, 2017Dicerna to Report Third Quarter 2017 Financial Results and Host Conference Call on November 2, 2017
finance.yahoo.com - October 26 at 1:51 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Upgraded by Zacks Investment Research to "Buy"Dicerna Pharmaceuticals, Inc. (DRNA) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - October 23 at 9:58 PM
Dicerna Files Clinical Trial Application for DCR-PHXC, the Company’s Most Advanced GalXC™ Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH)Dicerna Files Clinical Trial Application for DCR-PHXC, the Company’s Most Advanced GalXC™ Product Candidate, for Phase 1 Study in Primary Hyperoxaluria (PH)
finance.yahoo.com - October 16 at 6:42 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Rating of "Hold" from AnalystsDicerna Pharmaceuticals, Inc. (DRNA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 4 at 6:04 PM
Dicerna Pharmaceuticals, Inc. (DRNA) Expected to Post Earnings of -$0.75 Per ShareDicerna Pharmaceuticals, Inc. (DRNA) Expected to Post Earnings of -$0.75 Per Share
www.americanbankingnews.com - October 4 at 4:30 PM
ALNY In Top Form, LENS Catches Investors Eyes, PRQR, AXON Inch Closer To D-DayALNY In Top Form, LENS Catches Investors' Eyes, PRQR, AXON Inch Closer To D-Day
www.nasdaq.com - September 20 at 11:51 PM
Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable SeriesDicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series
finance.yahoo.com - September 20 at 6:50 PM
Dicerna Pharmaceuticals (DRNA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowDicerna Pharmaceuticals (DRNA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 12:21 AM

SEC Filings

Dicerna Pharmaceuticals (NASDAQ:DRNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dicerna Pharmaceuticals (NASDAQ:DRNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dicerna Pharmaceuticals (NASDAQ DRNA) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.